HIGHLIGHTS
- Who: Bindu Singh and collaborators from the San Antonio, Texas, USA have published the article: and is safe for concurrent use with cART during Mtb/SIV coinfection Texas Biomedical Research, in the Journal: (JOURNAL)
SUMMARY
HIV coinfection predisposes the host to reactivation of latent tuberculosis infection (LTBI), resulting in tuberculosis (TB) reactivation. Studies using the nonhuman primate (NHP) model of Mycobacterium tuberculosis (M. tuberculosis)/SIV coinfection show that CD4+ T_cell depletion due to SIV coinfections is insufficient in causing LTBI reactivation. While earlier introduction of combinatorial antiretroviral therapy (cART) significantly reduced the recruitment . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.